Background: Outcomes of continuous flow left ventricular assist devices (CF-LVADs) as bridge to transplant have significantly improved. The question has arisen whether patients on CF-LVADs have an increased risk of death on the waiting list as to justify a priority allocation (status 1). The aim of this study was to compare the survival after implantation of CF-LVADs with the survival on the waiting list for patients initially listed in United Network for Organ Sharing (UNOS) status 2.
Methods: All patients 18 years or older listed for heart transplantation (HT) in the United States between 2011 and 2013 in UNOS status 2 with no mechanical circulatory support at time of listing were analyzed. Patients were divided into 2 groups, depending on whether they received a new CF-LVAD while listed (CF-LVAD group) or not (NO-LVAD) and were further matched on their propensity score (PS) in a 1:2 ratio.
Results: Two hundred eighty-seven CF-LVAD patients were matched to 574 NO-LVAD patients. Survival after CF-LVAD was significantly lower at 24 months compared with waiting list (75.4 ± 4.4% vs 91.2 ± 8.9%, P < 0.0001). Further, survival was not significantly different between the 2 groups at 24 months after transplantation (81.3 ± 5.9% vs 86.7 ± 3.3%, P = 0.3).
Conclusions: Survival of patients listed in UNOS status 2 who receive a CF-LVAD while listed is significantly lower compared to patients who do not receive mechanical support on the waiting list. The current priority in the allocation system given to patients on CF-LVAD seems justified. Further posttransplant survival is not negatively influenced by previous CF-LVAD implantation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/TP.0000000000002105 | DOI Listing |
Int J Cardiol
December 2024
Northwestern University, Division of Cardiology, Chicago, IL, United States of America. Electronic address:
Background: Orthotopic Heart transplantation (OHT) is a definitive treatment for patients with advanced heart failure. Despite available evidence, recipients and some clinicians remain hesitant to accept organs from Increased Risk Donors (IRD). This study aims to report trends in acceptance of donors from IRD donors and long-term outcomes.
View Article and Find Full Text PDFTransplant Proc
November 2024
Department of Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Louisville Kentucky.
There are reports of successful lung transplants using SARS-CoV-2+ donors, but the data on their overall outcome is limited. We used the United Network for Organ Sharing Database (UNOS) to identify all lung transplant patients who received lungs from SARS-CoV-2+ donors between 2020 and 2023. There was no difference in survival between those who received lungs from SARS-CoV-2- and SARS-CoV-2+ donors (P = .
View Article and Find Full Text PDFJ Heart Lung Transplant
November 2024
Department of Surgery, University of Pittsburgh Medical Center Pittsburgh, PA. Electronic address:
J Clin Med
November 2024
Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Clin Transplant
November 2024
Leon H. Charney Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Background: Because of advances in medical treatment of heart failure, patients are living longer than in previous eras and may approach the need for advanced therapies, including heart transplantation, at older ages. This study assesses practices surrounding heart transplant in older adults (> 70 years) and examines short- and medium-term outcomes.
Methods And Results: This study is a retrospective analysis using the United Network for Organ Sharing (UNOS) database from 2010 to 2021.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!